Evidence map›Paper›PMID 29391313›Full record

ArticleThe Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology2018

Post-transplant malignancies in pediatric liver transplant recipients: Experience of two centers in Turkey.

Miray Karakoyun, Şebnem Önen, Maşallah Baran, Murat Çakır, Çiğdem Ömür Ecevit, Murat Kılıç, Mehmet Kantar, Serap Aksoylar, Funda Özgenç, Sema Aydoğdu

Abstract readMulticenter Study
In one paragraph

Article in The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. World journal of gastroenterology · 2019
    Pooled it
  2. Review
  3. Article
  4. Article
  5. Incidence ofSaudi journal of medicine & medical sciences
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Miray KarakoyunDepartment of Pediatric Gastroenterology, Hepatology and Nutrition, Tepecik Training and Research Hospital, İzmir, Turkey.
Şebnem ÖnenDepartment of Pediatrics, Ege University School of Medicine, İzmir, Turkey.
Maşallah BaranDepartment of Pediatric Gastroenterology, Hepatology and Nutrition, Katip Celebi University School of Medicine, İzmir, Turkey.
Murat ÇakırDepartment of Pediatric Gastroenterology, Hepatology and Nutrition, Karadeniz Technical University School of Medicine, Trabzon Turkey.
Çiğdem Ömür EcevitDepartment of Pediatric Gastroenterology, Hepatology and Nutrition, Prof. Dr. Behçet Uz Children's Hospital, İzmir, Turkey.
Murat KılıçDepartment of Transplantation and General Surgery, Kent Hospital, İzmir, Turkey.
Mehmet KantarDepartment of Pediatric Oncology, Ege University School of Medicine, İzmir, Turkey.
Serap AksoylarDepartment of Pediatric Oncology, Ege University School of Medicine, İzmir, Turkey.
Funda ÖzgençDepartment of Pediatric Gastroenterology, Hepatology and Nutrition, Ege University School of Medicine, İzmir, Turkey.
Sema AydoğduDepartment of Pediatric Gastroenterology, Hepatology and Nutrition, Ege University School of Medicine, İzmir, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimsA liver transplant is the preferred treatment for patients with end-stage liver disease, as it usually results in longterm survival. However, due to the use of chronic immunosuppressive therapy, which is necessary to prevent rejection, de novo cancer is a major risk after transplantation. The aim of this study was to assess the incidence of post-transplant malignancies in children after liver transplantations. MATERIALS AND

methodsThe study group consisted of 206 liver transplant recipients, with no history of cancer, including hepatocellular carcinoma, in two liver transplantation centers in Turkey between 1997 and 2015. Data were obtained from patient's data chart.

resultsIn the study group, de novo cancer was diagnosed in 13 of the 206 patients. Post-transplant lymphoproliferative disease (PTLD) occurred in seven (53.8%) patients and other malignancies in six of the 13 patients. The types of PTLD were as follows: B-cell origin (n=2), Epstein-Barr virus (EBV)-related (n=2), T-cell origin (n=1), and Hodgkin's lymphoma (n=2). EBV DNA was isolated from seven patients, three of whom developed PTLD. The others developed Kaposi's sarcomas, Burkitt's lymphomas, cutaneous large-cell lymphomas, Hodgkin's lymphomas, and liver sarcomas.

conclusionAfter transplantation, immunosuppressive treatment is unavoidable, increasing the risk of malignancies. However, a close follow-up and periodic screening can reduce cancer-related mortality and morbidity.

Indexed as

ChildChild, PreschoolFemaleHerpesvirus 4, HumanHodgkin DiseaseHumansImmunosuppression TherapyImmunosuppressive AgentsInfantLiver NeoplasmsLiver TransplantationLymphoproliferative DisordersMaleSarcoma, KaposiSkin NeoplasmsTurkeyImmunosuppressive Agents

Identifiers

PMID29391313
PMCPMC6322611

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.